Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study

Se Hoon Park, Young Saing Kim, Junshik Hong, Jinny Park, Eunmi Nam, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee, Min Chung

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


S-1 is an oral fluoropyrimidine consisting of the 5-fluorouracil prodrug tegafur combined with two modulating substances, gimeracil and potassium oxonate. On the basis of the potential additive effect between mitomycin C (MMC) and 5-fluorouracil as a continuous infusion, we conducted a phase II study to assess the efficacy and tolerability of the combination of S-1 and MMC as second-line chemotherapy for advanced gastric cancer (AGC). Patients with measurable AGC, progressive after one prior chemotherapy for metastatic disease, received MMC (7mg/m2) on day 1 and S-1 (40mg/m2) twice daily as an intermittent regimen of 4 weeks of treatment followed by a 2-week rest. Treatment was repeated every 6 weeks. The primary objective was the response rate. For 43 patients registered, 42 patients were treated with MMC plus S-1. A total of 121 chemotherapy cycles were delivered (median: 2; range: 1-6). The patients' median age was 53 years (range: 31-75) and nine (21%) had an Eastern Cooperative Oncology Group performance status of 2. In an intent-to-treat analysis, nine patients (21%) achieved an objective response, which was maintained for 4.1 months. The median progression-free and overall survivals were 3.4 months (95% confidence interval: 2.3-4.5) and 8.0 months (95% confidence interval: 6.1-9.9), respectively. Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable. One patient developed hemolytic anemia, which was resolved spontaneously. Grade ≥2 hand-foot syndrome was observed in only three patients. Second-line chemotherapy with MMC and S-1 is an active and tolerable regimen for AGC patients with good performance status.

Original languageEnglish
Pages (from-to)303-307
Number of pages5
JournalAnti-Cancer Drugs
Issue number3
StatePublished - Mar 2008


  • Mitomycin C
  • S-1
  • Second-line therapy
  • Stomach cancer


Dive into the research topics of 'Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study'. Together they form a unique fingerprint.

Cite this